Abstract
Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have